Department of Pathology, University of Medicine and Pharmacy of Targu Mures, Targu Mures (S.S.)
Regional Institute of Oncology, Iasi (C.T.), Romania
Vancouver General Hospital, Vancouver, British Columbia, Canada (L.H.)
Departments of Epidemiology and Biostatistics (Q.Z., A.I.)
Pathology (K.J.P., R.A.S.), Memorial Sloan Kettering Cancer Center, New York, New York
Ospedale Sacro Cuore Don Calabria, Negrar, Italy (A.P.)
Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel (S.A.R.)
Jikei University School of Medicine, Tokyo, Japan (T.K.)
Hospital de Oncología Mexico City, Mexico City, Mexico (I.A.C.)
Massachusetts General Hospital, Boston, Massachusetts (E.O.)
This study was approved by the institutional review boards of each participating center. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
This study was funded in part through the NIH/NCI MSK Cancer Center Support Grant P30 CA008748 (Dr R.A.S. and Dr K.J.P.).
The authors declare no conflict of interest.
Address correspondence to Simona Stolnicu, MD, Department of Pathology, University of Medicine, Pharmacy, Science and Technology of Targu Mures, 38 Gheorghe Marinescu Street, Targu Mures 540139, Romania. E-mail: [email protected].